Blood cancers

Ibrutinib and venetoclax “impressive” as first line combo in CLL

The combination of ibrutinib and venetoclax has shown “impressive” results in the first-line treatment of chronic lymphocytic leukaemia, an international expert says. The Phase II study published in the NEJM involving 80 previously untreated high-risk and older patients with CLL found that after 12 cycles of combined treatment, 88% of the patients had complete remission ...

Already a member?

Login to keep reading.

© 2021 the limbic